TB-500 vs ARA-290 (Cibinetida)
TB-500 is mainly studied for systemic recovery, mobility, tissue flexibility. while ARA-290 (Cibinetida) is studied for recovery, comfort, inflammatory balance. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| TB-500 | ARA-290 (Cibinetida) | |
|---|---|---|
| Category | Regenerative | Regenerative |
| Studied for | Systemic recovery, mobility, tissue flexibility. | Recovery, comfort, inflammatory balance. |
| How it acts | A fragment related to thymosin beta-4, studied for its role in systemic modulation of repair, flexibility and cell migration. | A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation. |
| Evidence level | Human trials available | Human trials available |
How they differ
Although sometimes mentioned together, TB-500 and ARA-290 (Cibinetida) do not target the same thing. TB-500: A fragment related to thymosin beta-4, studied for its role in systemic modulation of repair, flexibility and cell migration. ARA-290 (Cibinetida): A peptide studied for its relationship with tissue-repair pathways and modulation of discomfort associated with neural inflammation.
See full entry: TB-500 → · See full entry: ARA-290 (Cibinetida) →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between TB-500 and ARA-290 (Cibinetida)?
TB-500 targets systemic recovery, mobility, tissue flexibility. and ARA-290 (Cibinetida) targets recovery, comfort, inflammatory balance. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, TB-500 has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for TB-500 vs ARA-290 (Cibinetida) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteershuman J Cell Mol Med · 2021 · PMID 34346165 →
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trialhuman Cornea · 2015 · PMID 25826322 →
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) modelhuman Clin Ophthalmol · 2015 · PMID 26056426 →
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteershuman Ann N Y Acad Sci · 2010 · PMID 20536472 →
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber densityhuman Mol Med · 2013 · PMID 24136731 →
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabeteshuman Mol Med · 2015 · PMID 25387363 →
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Painhuman Invest Ophthalmol Vis Sci · 2017 · PMID 28475703 →
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edemahuman J Clin Med · 2020 · PMID 32674280 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.